Current partner codePEPTIDESDE
PeptideStat
Menu

Vendors

Compare pricesVendor directoryVendor reviewsDiscount codesLab tests & COAs

Research

ResearchDatabaseClinical trials

Tools

All calculatorsReconstitutionAccumulationUnit converterPeptide chemistry
NCT06654336·Phase 2·INTERVENTIONAL

Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC)

LeuprolideOtherRecruiting

Status

Recruiting

Phase

Phase 2

Enrollment

162

Locations

3

Results

Not posted

Publications

0

Study summary

What the protocol is testing.

The goal of this study is to determine whether the addition of Androgen Deprivation Therapy (ADT) utilizing the study drug ELIGARD® to Recurrence- Directed Therapy (RDT) improves progression-free survival (PFS) compared to RDT alone in patients with early radio-recurrent oligo-metastatic castrate / hormone sensitive prostate cancer (romCSPC). Participants will be assessed at standard of care clinic visits every 3 months. The follow-up period is 36 months.

Full detailed description

A multi-centre, open-label, phase II randomized clinical trial evaluating the addition of Androgen Deprivation Therapy (ADT) utilizing the study drug ELIGARD® compared to Recurrence Directed Therapy (RDT) alone in patients with previously localized prostate adenocarcinoma treated with definitive radiotherapy or with salvage radiotherapy after radical prostatectomy who experience biochemical recurrence and present with oligo-metastases (i.e., \< 5 sites of metastases) on conventional imaging. Eligible and consenting patents will be randomized in a 1:1 fashion to either RDT alone (standard arm) or RDT +ADT (ELIGARD®) x12 months (experimental arm). During treatment study participants will be assessed for disease progression, development of castrate resistant prostate cancer (CRPC), acute and late genitourinary (GU) and gastrointestinal (GI) radiotherapy toxicity, the occurrence of adverse events, initiation of tertiary therapy, overall survival and quality of life through the completion of participant questionnaires. Participants will be assessed at standard of care clinic visits every 3 months. The follow-up period is 36 months from the date of randomization. The planned sample size is 162 study participants.

Interventions

Treatment arms and agents.

RADIATION

Recurrence-directed therapy (RDT)

RDT options include radiotherapy or surgical resection.

DRUG

ELIGARD 22.5mg

ADT in the form of ELIGARD 22.5 mg every 3 months for a total of 12 months.

Timeline

From registration to results.

  1. First posted

    Oct 23, 2024

  2. Study start

    Mar 30, 2026

  3. Primary completion

    Apr 2031

  4. Study completion

    Jun 2031

  5. Results posted

    Not reported

  6. Registry updated

    Mar 13, 2026

Outcomes

What the study measures.

Primary outcomes

Composite progression free survival

Time frame · Time from randomization to the occurrence of composite PFS event occurring up to the 36 month follow-up.

Biochemical, radiological or clinical progression \[composite PFS (cPFS) event\]

Secondary outcomes

Disease progression

Time frame · Time from date of randomization, until the date of progression or death occurring up to the 36 month follow-up.

Disease progression: time to biochemical progression (bPFS) (proportion of bPFS events); Disease progression: proportion of conventional-imaging based progression (rPFS) (proportion of rPFS events); Disease progression: proportion with eugonadal progression (egPFS)

Time to initiation of tertiary therapy;

Time frame · Time of initial therapy to 36 month follow-up.

Any non-protocol treatment given for prostate cancer after protocol-specified intervention.

Proportion of patients that develop castrate-resistant prostate cancer (CRPC)

Time frame · During the 36 month follow-up.

Proportion of patients that develop castrate-resistant prostate cancer (CRPC)

Overall survival.

Time frame · During the 36 month follow-up.

Overall survival.

Rate of early and late Grade 3 or higher GU and GI toxicity.

Time frame · At 3, 6, 15 and 36 months.

The rate of early and late Grade 3 or higher GU and GI toxicity will be assessed at baseline, 3, 6, 15 and 36 months. The CTCAEv.5.0 (\> Grade 3, GI and GU) toxicity rates will be reported.

Quality of life assessed by EORTC QLQ C30

Time frame · Completed by the study participant at scheduled follow-up visits (Months 3, 6, 15 and 36).

Study participant reported quality of life utilizing the following measurement EORTC QLQ C30

Quality of life assessed by EORTC QLQ PR25 questionnaire

Time frame · Completed by the study participant at scheduled follow-up visits (Months 3, 6, 15 and 36).

Quality of life assessed by EORTC QLQ PRT20 questionnaire

Time frame · Completed by the study participant at scheduled follow-up visits (Months 3, 6, 15 and 36).

Eligibility

Who can take part.

Minimum age
18 Years
Maximum age
Not reported
Sex
MALE
Healthy volunteers
No

Inclusion Criteria: 1. Previous biopsy-proven localized prostate adenocarcinoma (without predominant features of sarcomatoid, small cell or neuroendocrine carcinoma) treated with definitive or salvage radiotherapy ≥ 2 years or more before enrollment. 2. Recurrent Oligo-metastatic CSPC, M0 on conventional imaging (bone scan and CT scan of chest/abdomen/pelvis) with ≤ 5 metastases cumulative on all imaging, including MRI and PSMA-PET. Note: Patients with conventional imaging M1 oligometastatic CSPC, who have no more than 5 metastatic sites in all imaging modalities including MRI and PSMA-PET, will be accepted for study enrollment. 3. All sites of recurrent disease must be amenable to treatment with radiotherapy or surgery in the judgment of the investigator. 4. Biochemical recurrent prostate cancer with ONE of the following PSA recurrence definitions: 1. After definitive radiotherapy (prostate in situ), with PSA ≥ nadir + 2ng/ml; 2. After prostatectomy and adjuvant/salvage radiotherapy, with PSA ≥ nadir + 0.2ng/ml. Exclusion Criteria: 1. Age \< 18. 2. ECOG Performance Status ≥3. 3. PSA ≥ 20 ng/ml. 4. Treatment with ADT within 2 years from study enrollment or treatment with any androgen receptor axis within 6 months from study enrollment. 5. Prior treatment with chemotherapy for prostate cancer or bilateral orchiectomy. Note: prior chemotherapy for a different type of cancer is allowed if the patient has been continuously disease-free for \> 3 years. 6. Intracranial or intrathecal metastasis. 7. Spinal cord compression, or spinal intramedullary metastasis. 8. Prior malignancy (except non metastatic, non- melanomatous skin cancer) unless disease free for \> 3 years. 9. Bilateral hip prosthesis, treated earlier with definitive prostate radiotherapy, who have evidence of local disease recurrence within the prostate and no option for salvage treatment with brachytherapy or surgery. 10. Previous documented hypersensitivity to ELIGARD® or other GnRH agonist analogs of components of such preparations.

Study locations

3 registered sites.

Canada. Showing up to 24 locations stored in the fast local snapshot.

Juravinski Cancer Centre

Hamilton, Ontario, Canada

The Ottawa Hospital Regional Cancer Centre

Ottawa, Ontario, Canada

Jewish General Hospital

Montreal, Quebec, Canada

Publications

Results and literature.

No PMID-linked publications were present in this registry snapshot.

Primary links

Continue at the source.

ClinicalTrials.gov ↗Search PubMed ↗Search FDA ↗Search EMA ↗

Related trials

More studies on Leuprolide.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.

TrialsLeuprolide trial dashboard →